前列腺素E1脂微球载体制剂治疗慢性重型肝炎的MELD评分变化

Changes of MELD score in patients with chronic severe hepatitis treated by Lipo-prostaglandin E1

关键词:  前列腺素E1脂微球载体制剂  慢性重型肝炎  MELD评分

Key words:  Lipo-prostaglandin E1  chronic severe hepatitis  Model of end-stage liver disease

摘要:

［目的］应用终末期肝病模型（MELD评分）评价前列腺素E₁脂微球载体制剂（Lipo PGE₁）对慢性重型肝炎的治疗作用。［方法］108例慢性重型肝炎随机分成治疗组、对照组，对照组53例予一般综合治疗，治疗组55例在一般综合治疗基础上加用Lipo PGE120 μg/d，疗程4周，观察两组治疗前后MELD评分的变化。［结果］ 治疗组患者治疗后MELD评分（22.18±10.08），与治疗前MELD评分（28.36±7.61）相比明显下降，差异有显著性意义，P<0.05；与对照组治疗后的评分（27.82±9.64）相比差异也有显著性意义，P<0.05。［结论］Lipo PGE₁对慢性重型肝炎有明显疗效，可改善病人的短期预后。

Abstract:

［Objective］To investigate the effect of Lipo PGE1 on patients with chronic sereve hepatitis by MELD (Model for end-stage live disease) prognosis analysis.［Methods］One hundred and eight patients with chronic severe hepatitis were divided randomly into treatment group and control group. 53 patients in the control group received general routine treatments, 55 patients in the treatment group received general routine treatments and Lipo PGE1 for 4 weeks, the MELD score and prognosis of diease were assessed between the two groups.［Results］In the treatment group, the MELD score of the after-treatment (22.18±10.08) was lower than that of the before-treatment (28.36±7.61), and the difference was significant in statistics,P<0.05. After 4 weeks treatment, the MELD score of the treatment group(22.18±10.08) was lower than the MELD score of the ofter-treatment of the control group(27.82±9.64), and the difference was significant in statistics,P<0.05.［Conclusions］Lipo PGE1 was obvious effect to treat chronic severe hepatitis, and can improve the short-term prognosis of patient.